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Simple Summary: High levels of Heat shock proteins (Hsps) in specific cancers are usually linked to
a poor prognosis, tumor progression, invasiveness, and resistance to treatment. Chaperone inhibition
could therefore be toxic for cancer cells due to their high dependence on chaperone activity to survive.
This study shows the potential to repurpose the small chemical compound pinaverium bromide,
currently used to treat functional gastrointestinal disorders, as a possible antitumor drug since it
displays a marked toxicity against two melanoma cell lines without affecting the viability of fibroblast
and primary melanocytes. This compound interacts with structural regions shared by representatives
of the Hsp70 and Hsp110 families, inhibiting the substrate remodeling ability of the Hsp70 system
in vitro and in a cellular context.
Abstract: Heat shock protein (Hsp) synthesis is upregulated in a wide range of cancers to provide
the appropriate environment for tumor progression. The Hsp110 and Hsp70 families have been
associated to cancer cell survival and resistance to chemotherapy. In this study, we explore the
strategy of drug repurposing to find new Hsp70 and Hsp110 inhibitors that display toxicity against
melanoma cancer cells. We found that the hits discovered using Apg2, a human representative of the
Hsp110 family, as the initial target bind also to structural regions present in members of the Hsp70
family, and therefore inhibit the remodeling activity of the Hsp70 system. One of these compounds,
the spasmolytic agent pinaverium bromide used for functional gastrointestinal disorders, inhibits
the intracellular chaperone activity of the Hsp70 system and elicits its cytotoxic activity specifically
in two melanoma cell lines by activating apoptosis. Docking and molecular dynamics simulations
indicate that this compound interacts with regions located in the nucleotide-binding domain and
the linker of the chaperones, modulating their ATPase activity. Thus, repurposing of pinaverium
bromide for cancer treatment appears as a promising novel therapeutic approach.
Keywords: chaperones; drug repurposing; inhibitors; melanoma; pinaverium bromide
1. Introduction
Molecular chaperones are key components of the proteostasis network that main-
tain the equilibrium between protein synthesis and degradation. This network regulates
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protein localization, prevents protein misfolding and aggregation, and keeps the native
conformation and function of proteins. It also assists in the clearance of hazardous protein
species by directing them to autophagy or proteasomal degradation, and in the reactivation
of protein aggregates when their formation cannot be avoided [1]. The collective function
of chaperones is essential to maintain cellular homeostasis leading to survival [2,3]. When
cells are exposed to physiological and environmental stresses, a significant increase in the
synthesis of these evolutionarily conserved and ubiquitously expressed proteins [4,5], also
known as heat shock proteins (Hsps), allows the cell to tackle otherwise lethal conditions.
In human cells, a combination of proteins of the Hsp40/J-domain protein (JDP), Hsp70
(Hsc70 and Hsp70) and Hsp110 (nucleotide exchange factor; NEF) families constitutes a
powerful protein remodeling system that forms part of the cellular protein quality control
system [1–5]. The highly versatile Hsp70 system favors different housekeeping activities,
including folding of newly synthesized proteins, transport of polypeptides across cellular
membranes, assembly/disassembly of protein complexes, and regulation of protein activ-
ity. It also performs stress-related cellular repair processes, such as prevention of protein
aggregation, refolding of misfolded proteins, and solubilization of aggregated proteins.
In addition, it collaborates with cellular degradation machineries to clear damaged pro-
teins. Among the different members of the Hsp70 family, the Hsc70 group is constitutively
expressed whereas the Hsp70 group is induced by cellular stress [1–3].
The representatives of the Hsp70 and Hsp110 families share their overall structure,
which contains two functional domains: the N-terminal nucleotide-binding domain (NDB)
responsible for ATP hydrolysis, and the C-terminal substrate-binding domain (SBD). A
conserved linker allows interdomain communication in Hsp70 [6]. The Hsp110 chaperone
family constitutes an Hsp70 divergent branch and, as compared with the Hsp70 family, it
has two main insertions in the SBD: an acidic subdomain and a C-terminal extension [7].
Besides being NEFs for Hsp70s, Hsp110 proteins have the ability to prevent protein ag-
gregation, promote protein folding, and confer thermotolerance to cells and thus function
as chaperones themselves [8–10]. Hsp70s, in contrast to representatives of the human
Hsp110 family, undergo a remarkable conformational change driven by ATP binding and
hydrolysis. In the ATP-bound state, the SBD has low affinity for substrates resulting in
fast association and dissociation rates. ATP hydrolysis triggers a conformational switch
resulting in higher affinity for substrates [11]. This conformational cycle, and, therefore,
the chaperone activity of Hsp70s, is tightly regulated through their cooperation with JDPs
and NEFs that fine-tune the ATP-dependent binding and release of the protein substrate.
The interaction of Hsp70 with a JDP and a client protein accelerates ATP hydrolysis by
Hsp70 and allows the efficient trapping and remodeling of the protein substrate [12,13].
Substrate release is modulated by NEFs, as Apg2, which replace ADP by ATP and reset the
Hsp70 chaperone cycle allowing binding of a new client [14].
Dysregulation of the expression of cytoprotective Hsps [15] under stress conditions
contributes to the development of several diseases including cancer [16]. Cancer cells
typically have higher metabolic needs and inappropriately activated signaling pathways
compared to normal cells and show a higher demand for chaperone activity to survive.
Cancer development involves an increase in oncogene levels by activating mutations in
those oncogenes and in tumor suppressor genes [16], whose folding and conformation
maintenance requires elevated levels of Hsp [17,18]. High levels of Hsp expression in
specific cancers is often related to a poor prognosis and plays an important role in sup-
pression of apoptosis, spontaneous as well as triggered by therapeutic intervention, which
aids in tumor progression, invasiveness and resistance to treatment [19–21]. Therefore,
inhibition of Hsps offers the possibility to target different oncoproteins and signaling path-
ways [22]. As other Hsp families, Hsp110 and Hsp70 have been related to poor prognosis
and malignancy in different types of cancer. Hsp110 overexpression has been linked to the
inhibition of apoptosis of transformed cells [23–25], cancer progression and chemotherapy
resistance [26–28]. Similarly, Hsp70 expression has been associated with tumor initiation,
progression and survival in a variety of cancer types [29,30]. Moreover, Hsp70 and Hsp110
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are integrated in the “epichaperome”, a chaperone network that bridges chaperones to
different cellular pathways, and is vital for tumor survival [31].
The aim of this study is to take advantage of drug repurposing to look for potential
Hsp110 and Hsp70 inhibitors for cancer treatment. Drug repurposing seeks to generate
novel clinical opportunities for known approved drugs [32]. Data from both pre-clinical
and clinical trials have clearly demonstrated antitumor efficacy of well-known and well-
characterized compounds within a wide range of drug classes beyond anticancer com-
pounds [33]. We chose Apg2, a representative of the human Hsp110 chaperone family,
as target for screening based on the finding that overexpression of this protein has been
related to different types of cancer [34–36]. Despite the importance of this finding, there is
only one reported Hsp110 inhibitor, which interacts with a cleft within the ATP binding
pocket of the chaperone, as suggested by molecular docking, and inhibits colorectal cancer
cell growth [34]. The search for potential Apg2 modulators was carried out by differential
scanning fluorimetry (DSF). This technique identifies protein binders as they often induce
a shift in the midpoint denaturation temperature (Tm) of the protein of interest upon
binding [37]. Ligand binding can induce protein stabilization if the ligand preferentially
binds to the native state, or destabilization when it interacts with a state(s) less stable than
the native one [38]. In the case of Hsp70s, NMR and computational studies have provided
a molecular view of the chaperone functional cycle with multiple conformational states
that might bind these ligands with different affinity [39]. If the stability of some of these
conformations were lower than that of the native state, ligand binding would result in
protein destabilization.
In this work, we screen the Prestwick Chemical Library of small molecule drugs,
searching for compounds that interact with Hsc70 and Apg2 chaperones and characterize
their effect on the remodeling activity of the Hsp70 system, using DnaJB1 as JDP. Our data
indicate that one compound, pinaverium bromide, inhibits the Hsp70 system in vitro and
in a cellular context compromising specifically the viability of two melanoma cell lines.
2. Results
2.1. High-Throughput Screening (HTS) and Validation of Modulators of Apg2
In this study we screened the Prestwick Chemical Library®, composed of 1280 off-
patent, 99%-approved drugs (FDA, EMEA and other agencies) selected for their high
chemical and pharmacological diversity, to find drugs that could be repurposed [40]. Since
all the compounds from the library are dissolved in DMSO, we first addressed whether this
solvent would modify the Tm of Apg2. The thermal stability of the protein was studied
by DSF between 30 and 90 ◦C at the highest DMSO concentrations (4%) used in this
study. The maximum from the first derivative of the temperature profile that gave the
Tm values (52.38 ± 0.03 ◦C without and 51.76 ± 0.25 ◦C with DMSO, respectively; n > 3)
showed that the solvent did not significantly affect the thermal stability of the protein. The
sample containing this solvent concentration was used as the reference in the screening.
Sypro Orange, the fluorescent dye used, is an indicator of protein unfolding as it interacts
with hydrophobic patches that the protein exposes during thermal denaturation [37].
Data obtained from the DSF experiments (Figure 1A) showed an initial low fluorescence
value that increased within a temperature interval, reaching a maximum fluorescence
signal upon protein unfolding. At post-denaturation temperatures, the fluorescence signal
decreased probably due to aggregation of the unfolded protein. The 15 compounds that
increased or reduced the Tm value (∆Tm)≥ 3-fold× SD of DMSO controls were considered
potential hits.
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Figure 1. Thermal stability of Apg2 reflects ligand binding. (A) Original DSF denaturation curves
(upper traces) and first derivative (bottom traces) of a destabilizing (∆Tm = −3.7 ◦C) compound.
Curves obtained in the absence (reference; black line) and presence of 400 µM of the corresponding
compound (grey line). The minimum and maximum fluorescence signals were given the values of
0 and 1, respectively. (B) Effect of increasing ligand concentration on the midpoint denaturation
temperature (Tm) and shift of the Tm of Apg2. Among the initial hits considered, compounds 1–6
induced a concentration-dependent shift of the midpoint denaturation temperature (∆Tm) of Apg2.
For data fitting, see Materials and Methods. The name, chemical structure, and molecular weight of
these compounds are shown in Table 1 and Figure S1.
Upon validation of the potential Apg2 binders by the effect of increasing compound
concentrations on the Tm of the protein, only six hits, all destabilizers, showed the ex-
pected concentration-dependent change in protein stability (Figure 1B), and they were
considered real binders and selected for further studies. The name and chemical structure
of these compounds are depicted in Table 1 and Figure S1, respectively. For stabilizing
ligands, fitting of the concentration dependent Tm values to Equation (2) in Cooper and
McAuley-Hecht (1993) [41] provides the Kd values if the enthalpy of the thermal transition
(∆H0) of the protein target is known. However, the complex conformational equilibrium
of Hsp110, and of chaperones in general, and the observed destabilizing effect of the
selected compounds [38] precluded estimation of the Kd values by DSF experiments, and
the concentration-dependent Tm-analysis (Figure 1B) was, thus, only used to validate
the binders.
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Table 1. Name, molecular weight, and therapeutic effect of the selected compounds.




































2.2. Apg2 Binders Also Interact with Hsc70
As mentioned, Apg2 harbors two regions that distinguishes it from Hsc70, namely
an acidic subdomain (AS) of 65 residues inserted in the β subdomain of the SBD, and an
extension of 141 amino acids at the C-terminus (Figure S2A). Both regions are predicted to
adopt mainly an intrinsically disordered structure [48,49] (Figure S2B).
To find out whether some of the selected compounds target these intrinsically disor-
dered regions (IDRs), their interaction with two variants of Apg2 that lack one of these
characteristic regions, namely Apg2∆AS and Apg2∆C, was studied by DSF (Figure S2C).
The results showed that although the thermal shifts observed for these deletion mutants
were in some cases different, they displayed a similar concentration dependence to the
full-length protein, suggesting that these compounds did not target specifically the acidic
subdomain and the C-terminal extension of Apg2. It thus appeared that the compounds
interacted with protein regions that might well be shared by Hsc70. If this were the case,
they could also bind to Hsc70 and, thus, this possibility was also explored with DSF. In
contrast to Apg2, Hsc70 undergoes a conformational cycle driven by ATP hydrolysis at
the NBD, which involves the allosteric rearrangement of its two domains [6,11]. Therefore,
the effect of the selected compounds on the thermal stability of Hsc70 was analyzed in the
presence of saturating nucleotide concentrations (ADP- and ATP-states) and in the absence
of nucleotide (apo-form). Data showed that the six compounds induced a significant
destabilization of Hsc70, especially of its apo-form, in a concentration-dependent manner
(Figure 2).
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Figure 2. Selected compounds also affect the thermal stability of free and nucleotide-bound Hsc70. (A–C) Titrations of
compounds 1–6 against apo-Hsc70 (A), Hsc70-ADP (B), and Hsc70-ATP (C). For fitting of the data, see Materials and
Methods. The name, chemical structure, and molecular weight of these compounds are shown in Table 1 and Figure S1.
2.3. Effect of the Compounds on the Chaperone Activity of Hsc70 and Apg2
G6PDH was used as a model client protein to follow the chaperone activity of the
binary (Hsc70/DnaJB1) and ternary (Hsc70/DnaJB1/Apg2) chaperone mixtures, as they
can reactivate aggregates of this substrate protein (Figure S3) and none of the compounds
significantly affected the activity of native G6PDH (Figure 3, insets). The addition of up to
2% DMSO (v/v) did not affect the functionality of the chaperones and, therefore, this was
the highest solvent concentration used in these experiments.
Compounds were added to the binary and ternary chaperone mixtures and in all
cases, a concentration-dependent inhibition of the refolding was observed after a 2-h
assay (Figure 3). As expected, the samples that did not contain Apg2 were also inhibited,
supporting the DSF data showing that the compounds also interact with Hsc70. The effect of
the compounds differed on the minimum concentration necessary to suppress reactivation
of G6PDH aggregates and, hence, on their half maximal inhibitory concentration (IC50)
values as shown in Table 2.
Table 2. IC50 values estimated for the inhibition of the aggregate reactivation ability of binary





Hsc70 + DnaJB1 Hsc70 + DnaJB1 + Apg2
1 11.9 ± 0.2 14.5 ± 1.8
2 58 ± 0.9 70.9 ± 0.1
3 10.1 ± 0.4 17.6 ± 0.1
4 37.3 ± 1.8 47 ± 5.6
5 106.8 ± 7.5 97.3 ± 21.1
6 18.7 ± 3.6 23.3 ± 3
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Figure 3. Chaperone-mediated reactivation of G6PDH aggregates in the presence of the selected
compounds. (A–F) The effect of compounds 1–6 on the Hsp70-based disaggregase system was
analyzed by following their effectiveness to reactivate G6PDH aggregates (0.4 µM) obtained after
denaturing and aggregating the client protein at 50 ◦C during 30 min. Samples contained 2 µM Hsc70
and 0.5 µM DnaJB1 either without (light grey) or with 0.4 µM Apg2 (orange). Values are shown as the
means ± SD of three independent experiments. Insets, effect of the highest compound concentration
on the activity of native G6PDH, relative to control samples without compound.
2.4. Toxicity of the Inhibitors in Human Melanoma Cell Lines
Compounds 1–6 inhibited, although with different effectiveness, substrate remodeling
by the Hsc70 system in a concentration-dependent manner. Due to the important role
of Hsps in the regulation of cancer development [50], we next analyzed whether these
compounds affected the growth of cancer cells. With that purpose, their toxicity was
assayed using the tumorigenic melanoma cell lines A2058 and MeWo. Among many other
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types of cancer, melanoma shows a direct relation between Hsp overexpression and disease
malignancy [51].
A2058 and MeWo cells were treated with increasing concentrations of compounds 1–6
and cell viability assays with XTT or Presto Blue were carried out at different incubation
times. Cell viability decreased with compounds 1, 2, 4, and 5 (Figure 4), whereas no toxicity
was observed for compounds 3 and 6 even at concentrations that exceeded four times
the IC50 values estimated with the isolated chaperone system). Compound 1 had the
highest inhibitory effect but it was discarded from the study based on published work
that reported its toxicity in several non-transformed cell lines [52–54]. Compounds 2 and 5
showed an expected time-dependent toxicity, with a general difference in their effectiveness
between the two melanoma cell lines, being more toxic for A2058 as compared to MeWo
cells (Figure 4). With compound 4, a decreased potency over time was observed (Figure 4),
which could be attributed to compound chemical instability, compound efflux or drug
inactivation, among others [55].
Figure 4. Cytotoxic effect of the studied compounds on A2058 and MeWo cells. (A–B) Dose and time-dependent effect
of compounds 2, 4, and 5 on the viability of (A) A2058 and (B) MeWo cells. Cells were treated with the concentrations
indicated during 4.5, 8, and 12 h. Following treatment either XTT or Presto Blue were added, and samples were measured in
a spectrophotometer after 4 or 2 h, respectively. The values are expressed as means ± SD obtained from three independent
experiments.
The viability results were confirmed by cell culture images (Figure S4), which showed
increased cell shrinkage and membrane blebbing, indicative of cell death, when compared
to non-treated cells [56]. Images of treated cell cultures were not taken at longer incubation
times because the cells detached from the flask surface upon cell death.
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2.5. Melanoma Cell-Specific Inhibition by the Selected Compounds
Once confirmed that compounds 2 and 5 were toxic for the melanoma cell lines A2058
and MeWo, it was necessary to address whether their effect was specific for cancer cells.
Based on the initial hypothesis, transformed cells rely to a greater extent on Hsps than
normal cells do and, hence, inhibition of the target proteins would be more detrimental
to the former. To find out if this was the case for these compounds, two human control
cell lines were selected: melanocytes (HEMn-LP non-malignant skin cells) and fibroblasts
(MRC-5). Melanocytes were primary culture cells from skin and fibroblasts immortalized
cells. Control cell lines were treated with compounds 2 (40 µM) and 5 (20 µM), and no
toxicity was observed in either case. Thus, melanocytes and fibroblasts were resistant to
these molecules while they caused cell death in A2058 and MeWo cells in the conditions
tested (Figure 5A,B).
Figure 5. The selected compounds do not compromise the viability of melanocytes and fibroblasts whereas they are
cytotoxic on melanoma cell lines. Time-dependence of the viability of the four cell lines after treatment with compounds
2 (40 µM) (A) and 5 (20 µM) (B). While melanoma cell viability decreased with time, neither fibroblasts nor melanocytes
reduced their viability after 12 h. Following treatment, either XTT or Presto Blue were added, and the absorbance of samples
was measured in a spectrophotometer after 4 or 2 h, respectively. Values are expressed as mean ± SD obtained from three
independent experiments; 100% viability refers to each cell line without compound. Lines in panels A and B are to guide
the eye.
Toxicity of compound 5 with the melanoma cell lines was observed at around 7-fold
lower concentrations than the IC50 values determined for the isolated chaperone system,
suggesting that this compound could have additional targets (see discussion). As this
makes it considerably more difficult to characterize the action of the potential drug and
control the emergence of side effects, compound 5 was omitted from the study at this stage
and research continued with compound 2 (Pinaverium bromide; PB).
2.6. Pinaverium Bromide (PB) Causes Melanoma Cell Death by Inducing Apoptosis
To explore whether PB could lead to melanoma cell apoptosis, we performed im-
munofluorescence assays to detect activated caspase-3, one of the apoptosis effector
/executioner caspases [57]. Results showed that 40 µM PB induced caspase-3-dependent
apoptosis after 3.5- and 7.5-h treatment in A2058 (Figure 6A) and MeWo cells (Figure S5),
respectively. A shorter incubation time was used with A2058 cells due to its higher sen-
sitivity to PB causing loss of viability and cell detachment from the culture flask over
time. Additionally, melanoma cell cultures treated with 40 µM PB were recorded for 8 h
(A2058) and 24 h (MeWo) to monitor compound-induced morphological changes prior to
cell death (Figure S6). Detection of active caspase-3 in A2058 cells but not in melanocytes
upon exposure to a toxic PB concentration further reinforces apoptosis as the main cause of
cell death (Figure 6B and Figure S7).
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Figure 6. Detection of activated caspase-3 in A2058 cells as an indicator of apoptosis. (A) A2058 cells in the absence (control
panel) and presence of PB (40 µM). Samples were stained for activated caspase-3 (red) as an indicator of apoptosis and cell
nuclei (blue) were detected with 4′,6-diamidino-2-phenylindole. (B) Immunoblot of caspase-3 corresponding to human
melanocytes (HEM) and A2058 cells treated 12 h with 20 µM PB. GAPDH is used as loading control.
2.7. Identification of PB Binding Site by Docking and Molecular Dynamics
We resorted to molecular modeling to identify the potential binding site of PB in its
targets, and to describe the network of protein–ligand interactions that could stabilize the
complexes. To this aim, we first performed blind protein–ligand docking experiments with
GaudiMM [58] to assess the most likely binding site of the drug, and afterwards the most
accurate orientation was generated with GOLD [59]. Finally, large-scale classical molecular
dynamics (MD) was performed on the best solutions of the docking experiments to explore
how compound binding affected protein motions.
As PB bound to Apg2 and to the ADP- and ATP-states of Hsc70, it was reasonable to
suggest that this drug should interact with a region shared by these proteins. Therefore,
docking solutions were filtered focusing on regions that appear in these structures. The
initial blind docking performed with GaudiMM allowed us to discriminate two potential
binding pockets (Figure S8). The first site, which had the higher density of docking
solutions, showed interactions with the NBD domain and the linker (Figure S8A). The
second site involved only residues located on the NBD domain, mainly at the external
region of the IA subdomain (Figure S8A).
When a more detailed docking to these protein regions was carried out with GOLD, PB
showed better binding to the first site for Apg2, Hsc70-ADP, and Hsc70-ATP, although the
difference was stronger for the Hsc70-ATP state. Based on these results, we considered this
site at the region connecting the NBD and SBD subdomains (Figure 7B) the most probable
location for PB. We next performed MD simulations (100 ns) on the best docking solution,
the PB/Hsc70-ATP complex, to explore its stability and to identify the residues involved
in complex formation. As the ligand remained in the same location, with only minor
changes in orientation, the interaction of the compound with the protein was statistically
analyzed with Cytoscape [60] as implemented in UCSF Chimera [61] (Figure 7B). Results
showed that residues from subdomains IA and IIA of the NBD (L210, F217, and V219 and
A148, F150, R155, R171, I172, I173, N174, P176, T177, and Q376, respectively) and from the
linker (D390, L391, L393, L394, D395, V396, and P398) were involved in complex formation.
They also suggested that binding is dominated by Van der Waal interactions, and thus
that complex stabilization largely depends on hydrophobic contacts (Figure 7B). These
findings are consistent with the high hydrophobicity of both the ligand and the binding
site. Docking also suggested the same binding site in Hsp70 (Figure S8B). As expected,
sequence alignment showed that the amino acids engaged in PB binding are conserved in
the three proteins (Figure S8C).
The involvement of these protein regions in complex formation indicates that PB bind-
ing might affect the ATPase activity of these proteins. To test this possibility, we analyzed
the ATP-hydrolysis rate of Hsc70, Hsp70, and Apg2 at increasing compound concentrations
(Figure 7C). The results showed that PB inhibited 23–28% and 35% of the ATPase activity
of Hsp70-Hsc70 and Apg2, respectively, in a concentration-dependent manner.
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Figure 7. PB binds to Hsc70 and Apg2 through interactions with the NBD and the linker and impairs their ATPase activity.
(A) Best docking results of PB (green) with Hsc70 in ADP and ATP states, and with Apg2. (B) Interactions between PB
(green) and Hsc70-ATP (light grey) that allow the compound to be stable in the initial predicted binding pocket after a MD
simulation of 100 ns. Interacting residues are grouped and colored depending on their location in the three-dimensional
structure of the protein: IA subdomain of the NBD in pink, NBD IIA subdomain in yellow and the linker in blue. (Left panel)
Interaction network between PB and Hsc70 in ATP state performed after analyzing the MD simulation of this complex
using Cytoscape. Bold lines correspond to the most frequent and thus, the most stabilizing interactions. (Right panel)
Representative frame of the PB-Hsc70 complex during the simulation. (C) Effect of PB on the ATPase activity of Apg2,
Hsc70, and Hsp70. Increasing concentrations of the compound were added to 6 µM Hsc70 (white), 6 µM Hsp70 (grey), or
2 µM Apg2 (orange). The ATPase activity of the chaperones showed a concentration-dependent inhibition in the presence
of PB. Values are expressed as means ± SD obtained from three independent experiments.
2.8. PB Inhibits Luciferase Protein Refolding in a Cellular Context
To explore if PB inhibited the activity of the Hsp70 system in a cellular context, we
resorted to study its effect on the chaperone-mediated substrate protein recovery after
heat shock. To this aim, Hsp70 (HspA1A) was used, instead of Hsc70 (HspA8), as it was
found to be significantly more efficient to refold luciferase after heat shock, in agreement
with a previous study [62]. HEK-293 cells co-expressing luciferase and Hsp70 or GFP as
a control were subjected to heat shock conditions (45 ◦C, 30 min), and the recovery of
luciferase activity was monitored after the thermal stress in the absence and presence of
two PB concentrations toxic for melanoma cell lines (Figure 8). Hsp70 showed a high
activity on luciferase refolding compared to control cells co-expressing GFP (Figure 8A),
as previously reported [62]. Interestingly, PB concentrations that induced death of the
two melanoma cell lines without affecting the viability of non-tumor cells (Figure 5),
including HEK-293, inhibited luciferase recovery, which became similar to that of the
control sample expressing GFP instead of Hsp70 (Figure 8). This is clearly observed at
30 µM PB, compound concentration that did not significantly change the amount of active
luciferase before the heat shock. At 40 µM PB, the 28% inhibition observed under non-stress
conditions is lower than the 58% decrease estimated after thermal stress (Figure 8).
Taken together, our results reveal that PB inhibits the intracellular chaperone activity
of the Hsp70 system and induces apoptosis in the tumorigenic melanoma cell lines A2058
and MeWo but not in non-malignant skin cells, melanocytes, and fibroblasts.
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Figure 8. PB inhibits Hsp70-mediated refolding of luciferase in HEK-293 cells. Luciferase-encoding
plasmids were co-transfected with plasmids encoding Hsp70 or GFP. Cells were subjected to heat
shock (HS), 45 ◦C during 30 min, and after a recovery period of 2 h at 37 ◦C in the absence or presence
of PB (30 and 40 µM) as indicated, luciferase activity was measured. Values for samples co-expressing
Hsp70 are expressed relative to that obtained for the unheated control in the absence of PB (white
striped column). For cells co-expressing GFP, 100% was the corresponding control without HS (white
dotted column). Statistical analysis of the heated samples (grey columns) was performed considering
as 100% the luciferase activity obtained without thermal stress for each experimental condition (white
columns). Data are presented as mean ± SD of three independent experiments (* p < 0.05; ** p < 0.01).
3. Discussion
We first aimed to identify compounds that could specifically target Apg2, a member
of the Hsp110 family, without interacting with Hsc70. The peculiarities of Apg2 compared
to Hsp70, namely an insertion in the SBD and an extension at its C-terminus [49], were
considered appealing enough to try to find modulators that would bind to the mentioned
regions and, hence, be specific for Apg2. However, the six compounds selected as hits
for analysis after the screening and validation of the Apg2 modulators do not interact
with these Apg2-specific IDRs. This is supported by the finding that they bind to deletion
variants of the protein that lack the specific regions that differentiate it from Hsc70. This is
not surprising, as it has been proven difficult to identify or design small chemical molecules
that specifically bind to intrinsically disordered proteins (IDPs) [63,64]. Thus, it was not
unexpected that these compounds also interacted with Hsc70 as revealed by DSF and by
their inhibitory effect on the refolding activity of both the ternary (Hsc70/DnaJB1/Apg2)
and binary (Hsc70/DnaJB1) chaperone complexes. Therefore, they most probably bind to
structural regions shared by the two proteins, as suggested by ATPase, molecular docking
and MD studies, being Hsp110 binders also capable of associating to Hsc70 and Hsp70.
Among the distinct Hsp families, Hsp70 is considered the hub that connects the different
branches involved in maintaining protein homeostasis (proteostasis): folding, trafficking
and degradation [65]. Hsp70 has been implicated in the bad prognosis of cancer as its
overexpression has been linked to anticancer drug resistance, inhibition of cell apoptosis
and increasing survival rates under otherwise adverse conditions [30,66,67].
Melanoma is the most aggressive form among the different skin cancers [68]. The
incidence and mortality rate of malignant melanoma has been increasing worldwide. Its
treatment mainly depends on the time of diagnosis, as it becomes refractory to conven-
tional therapies in the metastatic stage [69]. Therefore, it is necessary to develop new drugs,
which by themselves or in combination with existing medications can overcome the resis-
Cancers 2021, 13, 2936 13 of 24
tance against chemotherapy and induce cell death, an approach that includes the possible
repositioning of old drugs for new treatments. Drug repositioning or repurposing aims to
find new therapeutic uses to approved drugs beyond the original medical indication they
were given [70]. Furthermore, this field has allowed the development of polypharmacology,
which is based on the fact that a certain molecule can target several targets associated to
multifactorial diseases [71].
Several studies have shown that Hsp110 and Hsp70 are overexpressed in melanoma,
as in other cancers [72,73], playing a key role in cancer progression/prognosis and drug
resistance [74]. Cancer cells with higher metabolic needs and hyperactivated signaling
pathways, exhibit a stronger demand for chaperone machineries to survive [15]. It has
been suggested that in melanoma cells, their tumorigenic potential seems to correlate
with the ability to disable apoptosis, a process in which Hsp70 is a key regulator [74,75].
Hsp70 binds and inactivates a number of pro-apoptotic molecules, i.e., caspase 3/7, and
thereby delays cell death [22,76,77]. Elevated chaperone levels block the apoptotic pathway
at different stages. Therefore, Hsp70 inhibitors show tumor-selective cytotoxicity, with
limited toxicity in normal cells [74]. Hsp70 is an obligate co-chaperone for Hsp90, and
targeting the latter has shown a key role in the treatment of melanoma [78]. It has been
hypothesized that combining Hsp70 and Hsp90 inhibitors might lead to enhanced activ-
ity [30,78,79]. However, interestingly, it has also been demonstrated that inhibition of just
Hsp70 considerably modifies and severely damages the Hsp90 chaperone system, pointing
to Hsp70 as a new therapeutic objective for melanoma [30,79].
Cell viability experiments showed that among the six compounds that bind Apg2
and Hsc70, only PB induced cell death at concentrations close to those described in the
reactivation assays and inhibits the intracellular chaperone activity of the Hsp70 system,
thus suggesting that inhibition of this chaperone system might be behind the observed
toxic effect. As desired, toxicity was only detected in the two cancer cell lines and not
in fibroblast or melanocytes, indicating that it could be related to their strict chaperone-
dependent proliferation. Inhibition of the Hsp70 system was therefore expected to cause cell
death in the metabolically demanding melanoma cell lines. This compound, as suggested
by molecular docking and MD simulations, interacts with a conserved chaperone surface
made of residues from subdomains IA and IIA of the NBD and the linker. This binding
mode could explain the effect of the compound on both members of the Hsp70 family
and Apg2, and the inhibitory effect on the complete Hsp70 chaperone system. Loss of cell
viability at compound 5 (Mefloquine Hydrochloride, MH) concentrations around seven-
fold lower than those observed in the aggregate refolding assays, most likely indicates that
the effect of this drug could be due to a mechanism different from chaperone inhibition.
Indeed, it has been reported that similar MH concentrations exert antiproliferative effects
through an increased lysosomal biogenesis and activation, followed by oxidative stress,
lysosomal lipid damage and functional impairment [80].
This work suggests that PB could be repurposed as an inhibitor of Hsp70 for melanoma
treatment. This compound is a spasmolytic agent used for functional gastrointestinal
disorders. PB action restores normal bowel function, relieving spasm and pain, transit
disturbances and other symptoms related to motility disorders and may be considered as
effective first-line therapy for patients with irritable bowel syndrome [81]. It is known that
PB functions as an atypical calcium antagonist that interacts with the 1,4-dihydropyridine
binding sites on voltage dependent L-type calcium channels, located on gastro intestinal
smooth muscle cells, in a competitive manner [82]. Based on this mechanism of action
and on the involvement of calcium channels in cell cycle progression, it has been pro-
posed that existing calcium channel blockers may be used in combined therapies against
melanoma [83]. Our results show that this compound also inhibits the intracellular chaper-
one activity of the Hsp70 system, and thus point to Hsp70 as an alternative target of PB
that could be, at least in part, responsible for its marked toxicity against two melanoma
cell lines without compromising the viability of fibroblast and primary melanocytes. The
around two-fold difference in the IC50 values estimated for PB in cell death assays (around
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10–33 µM for A2058 and MeWo melanoma cell lines, respectively; Figure 4) and in vitro
reactivation experiments (55–70 µM; Table 2), could be due to its possible action on dif-
ferent targets, such as calcium channels (see below) and the Hsp70 system, which might
exert a synergistic effect that would result in an increase cell toxicity [71]. This has been
considered a potential advantage of drug repurposing, as a drug active on multiple tar-
gets may be characterized by an improved efficacy when compared to a more selective
pharmacological agent.
The comparison of the PB-induced toxicity in the two melanoma cell lines also suggests
that A2058, which has a doubling time significantly shorter than that of MeWo, 30 and 40 h,
respectively, is more sensitive to the compound. This result is expected, as the accelerated
metabolism needed to proliferate faster depends to a higher extent on the chaperone
machinery [29]. A2058 cells, in contrast to MeWo, harbor a point mutation (V600E) in the
BRAF gene [84] that is considered a proto-oncogene coding for a serine/threonine kinase.
In line with the doubling time differences between A2058 and MeWo cells, mutations in
BRAF are related to an accelerated proliferation [85]. PB induces cell death by activating
apoptosis in the two melanoma cell lines as determined by the detection of active caspase-3
in treated-cells [57]. Blebbing, another apoptotic hallmark, was identified in both A2058
and MeWo cells, as determined by time-lapse cell culture analysis.
It is now generally accepted that Hsps play a pivotal role in tumor progression and
resistance to current therapies and thus, they appear as potential targets in the development
of new cancer treatments [72]. This study has identified an inhibitor of the human Hsp70
system and is capable of inducing cell death via apoptosis in the melanoma cell lines A2058
and MeWo without affecting the viability of melanocytes and fibroblasts. It remains to be
explored whether PB could be used as a monotherapy without the undesired toxicity shown
by other Hsp70 and Hsp90 inhibitors that limits their clinical efficacy [86], or, alternatively,
it could be administered in combination with standard chemotherapeutic agents [87] or
other Hsp inhibitors [29] to enhance their antitumor potency.
4. Materials and Methods
4.1. Cloning, Expression and Purification of Proteins
The cDNAs of Apg2 (HSPH2), Hsc70 (HSPA8), and DNAJB1 were obtained from
Addgene and cloned into pE-SUMO vector (LifeSensors, Malvern, USA). The mutants
Apg2∆AS and Apg2∆C, carrying a deletion from residue 504 to 569 and 702 to 840, re-
spectively, were cloned by fusing two PCR fragments corresponding to the upstream and
downstream sequences of these protein segments [88] and verified by sequencing. Recom-
binant proteins containing a tag with 6 histidines and SUMO fused to the N-terminus were
expressed in BL21 Rosetta cells and purified with a first step of affinity chromatography
using NiNTA (Qiagen, Hilden, Germany) columns, followed by treatment with His-Ulp1 to
cleave the tag, and a final NiNTA column in which the pure protein eluted in the unbound
fraction [89].
4.2. Differential Scanning Fluorimetry (DSF)
High-throughput screening was carried out using DSF with 0.1 mg/mL Apg2, Apg2
∆L or Apg2 ∆C in 25 mM Hepes pH 7.6, 2, 0.01% TX-100, 2 mM DTT and 5x Sypro Orange
dye (Sigma-Aldrich, St. Louis, MI, USA). Protein samples (9.6 µL) were placed in 384-well
PCR plates (Thermo Fischer Scientific, Waltham, MA, USA) and compounds from the
Prestwick Chemical Library® (1280 compounds dissolved in DMSO at a concentration of
10 mM) were added to a final concentration of 400 µM and 4% DMSO. Each plate had
16 control wells with 4% DMSO but without compounds. Plate preparation was done
using the Bravo Automated Liquid Handling Platform (Agilent, Santa Clara, CA, USA).
Apg2 validated binders were similarly tested with Hsc70. In this case, samples contained
0.1 mg/mL protein in 40 mM Hepes pH 7.6, 50 mM KCl, 5 mM MgCl2, 0.01% TX-100, 2 mM
DTT and 5 × Sypro Orange in the absence or in the presence of 2 mM ADP or 2 mM ATP.
Plates were loaded into a RT-PCR Light Cycler 480 II (Roche, Basel, Switzerland). Thermal
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unfolding curves were recorded from 30 to 90 ◦C at 2 ◦C/min scan rate by following the
Sypro Orange fluorescence intensity (λex = 465 nm, λem = 580 nm) associated with protein
unfolding. Validation of the selected hits was carried out by testing at least eight different
compound concentrations within the concentration range 0.195–400 µM in a final volume
of 12.5 µL using 96-well PCR plates (Thermo Fischer Scientific). Sample buffer and assay
conditions were the same as above.
Analysis of the experimental unfolding curves was carried out as reported [90]. Flu-
orescence data were smoothed and the first derivative of the thermal unfolding curves
were calculated. The Tm-values were obtained as the maxima of the first derivative of
the experimental unfolding curves. Compounds that altered the Tm value ≥ 3-fold ×
standard deviation (SD) of the Tm for DMSO controls (Tm0) were considered potential
hits. The concentration dependent Tm-values were fitted to Equation (2) in Cooper and
McAuley-Hecht [41].
4.3. G6PDH Aggregate Reactivation
G6PDH (2.5 µM) was heat-denatured and aggregated for 30 min at 50 ◦C in 50 mM
Tris-HCl pH 7.5, 150 mM KCl, 20 mM MgCl2, and 10 mM DTT. Subsequently, aggregates
were stabilized for 30 min at 30 ◦C. The properties of these aggregates have been previously
reported, and typically show a hydrodynamic radius of approximately 500–600 nm [91].
Aggregates (0.4 µM final concentration) were added to samples containing 2 µM Hsc70
and 0.5 µM DnaJB1 in the absence or presence of 0.4 µM Apg2. The assay buffer also
contained 0.01% TX-100 and 1–2% DMSO to avoid self-association of the compounds
and maximize compound solubility. A preincubation of the samples with compounds for
30 min at 30 ◦C was done prior to starting the reaction. The reaction was started with the
addition of 2 mM ATP and the ATP-regeneration system (3 mM PEP and 20 ng/mL PK).
Final sample volume was 100 µL. Reactivation was monitored at 30 ◦C for 180 min. At
different times of the reaction, 5 µL of sample were added to 250 µL buffer containing
50 mM Tris-HCl pH 7.5, 50 mM KCl, 20 mM MgCl2, 10 mM DTT, 1 mM NADP+, 2.5 mM
G6P (Sigma-Aldrich). NADPH formation was measured recording the absorbance increase
at 340 nm in a Synergy HTX plate reader (BioTek, Winooski, VT, USA) in transparent
96-well plates with flat bottom (Sarstedt, Newton, NC, USA) for 5 min. Reactivation
percentages were calculated considering the slope of NADPH formation for native G6PDH
as 100% activity. Aggregates not treated with chaperone gave the spontaneous reactivation
(below 5%) that was established as 0% reactivation. IC50 values were estimated with a
sigmoidal dose-response ligand-binding equation.
4.4. ATPase Measurements
Steady-state ATPase activity was measured using the assay described by Nørby [92].
Briefly, Assays were performed at 30 ◦C in 40 mM Hepes, pH 7.6, 50 mM KCl, 5 mM Mg
acetate, and 1 mM ATP, using transparent 96-well plates with flat bottom (Sarstedt), a
final volume of 200 µL and 6 µM Hsc70 or 2 µM Apg2. Assay buffer also contained 0.01%
Triton X-100 (TX-100) and 1–2% dimethyl sulfoxide (DMSO). ATP consumption rates (µmol
ATP/min) were calculated from the slopes of the A340 decay curves over the selected time
intervals that showed a linear absorbance decline. The amount of ATP moles hydrolyzed
per min was calculated measuring the absorbance decay at 340 nm during 1 h in a Synergy
HTX plate reader (Biotec, Emmerich am Rhein, Germany), using the extinction coefficient
of NADH (ε340 6220 M−1 cm−1).
4.5. Cell Culture
Tumorigenic skin melanoma cell lines A2058 (ATTC® CRL-11147™) and MeWo
(ATTC® HTB-65™) were obtained from the American Type Culture Collection (Rockville,
MD, USA). Cells grew in Dulbecco’s Modified Eagle Medium (DMEM) high glucose
(Sigma-Aldrich) supplemented with heat-inactivated 10% fetal bovine serum (FBS) (Hy-
Clone™, GE Healthcare, IL, USA). Lung MRC-5 fibroblasts (ATTC® CCL-171™) from the
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American Type Culture Collection (Rockville, USA) were grown in Roswell Park Memorial
Institute (RPMI) Medium 1640 + GlutaMAX™ (Gibco™, Life Technologies, Carlsbad, CA,
USA) supplemented with heat-inactivated 10% FBS. Primary human melanocytes (human
epidermal melanocytes, neonatal, light pigmented, HEMn-LP) were purchased from Invit-
rogen (Waltham, MA, USA, C-002-5C). Cells were grown in Cascade Biologics Medium
254 (Gibco™, Life Technologies) supplemented with Cascade Biologics HMGS-2 (Gibco™,
Life Technologies).
All cell lines were grown at 37 ◦C in a 5% CO2-95% air-water saturated atmosphere
in 25 or 75 cm2 flasks as exponentially growing subconfluent monolayers. Cells were
examined during culture with an inverted microscope Olympus CK-2 (Olympus, Waltham,
MA, USA) and regularly passaged at subconfluency. Prior to detachment, cells were washed
with PBS and treated with 0.05% trypsin-EDTA (Gibco™, Life Technologies) for 5 min at
37 ◦C. Trypsin was inactivated by the addition of FBS (except for primary melanocytes)
and diluted twice by adding new fresh growth medium. Cells were centrifuged at 4 ◦C and
300× g for 5 min, and the resulting pellets were resuspended and quantified in a TC20™
Automated Cell Counter (Bio-Rad, Madrid, Spain) with trypan blue staining. Cells were
plated at 1:2–1:10 dilutions in a final volume of 10 mL (75 cm2 flasks) or 5 mL (25 cm2
flasks) in the corresponding growth medium.
4.6. Recovery of Intracellular Luciferase Activity
pcDNA5/FRT/TO HSPA1A (Addgene) was used to express the human inducible
Hsp70, pRSVLL/V [93] encoding for cytoplasmic firefly luciferase (cyt-luciferase) was kindly
provided by Harm H. Kampinga, University of Groningen [94], and pcDNA5/FRT/TO
GFP (Addgene) was used as a control. HEK (human embryonic kidney)-293 cells were
grown in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% FBS
(Gibco). Cells (2.0 × 105) were seeded in an 8.87-cm2 culture dish (Sarstedt). After 24 h,
they were transfected with 1.5 µg pRSVLL/V with Lipofectamine® 2000, following the
DNA Transfection Reagent Protocol (Invitrogen). When required, cells were cotransfected
with pcDNA5 HSPA1A (1.5 µg) or with pcDNA5 GFP so that in all experiments the total
plasmid quantity was 3 µg/8.87-cm2 dish. Moreover, 48 h after transfection cells were
subjected to heat shock (45 ◦C, 30 min in a water bath). The medium was replaced by
DMEM supplemented with 1% FBS containing cycloheximide (20 µg/mL) 30 min before
the heat shock. After heat shock, 30 or 40 µM of PB was added to the corresponding
samples and 0.9% DMSO to the controls, and the plates were placed in a CO2 incubator
at 37 ◦C for 2 h. Afterwards, cells were washed with ice-cold phosphate-buffered saline
(PBS), lysed in 300 µL of luciferase lysis buffer (25 mM H3PO4/Tris, pH 7.8, 10 mM MgCl2,
1% Triton X-100, 15% glycerol, 1 mM ethylenediaminetetraacetic acid) containing 0.5%
2-mercaptoethanol, and luciferase activity was measured in a Synergy HTX plate reader
(Biotec) after the addition of 50 µL of Luciferase Assay Reagent (Promega, Southampton,
UK) to 100 µL of sample. The activity of samples that were treated in the same way, but
with the heating step replaced by a 30 min incubation on ice, was taken as 100% for each
condition, as previously reported [62].
4.7. Immunocytochemical Staining
Immunofluorescence was used to detect activated caspase-3 in A2058 and MeWo
cells treated with 40 µM PB; 40,000 cells/well of A2058 or MeWo were plated in poly
L-lysine-coated 8-well chambered coverslips (µ-Slide 8 well, Ibidi, Grafelfing, Germany)
in 300 µL DMEM supplemented with 10% FBS and incubated overnight at 37 ◦C. The
following day, the medium was replaced by 300 µL DMEM supplemented with 1%FBS and
0.9% DMSO in the presence or absence (controls) of 40 µM PB. A2058 and MeWo cells were
incubated for 3.5 or 7.5 h, respectively. The two melanoma cell lines were not subjected
to the same incubation times due to their different sensitivity to PB. In both cases, the
incubation time aimed at obtaining samples where death occurred without cell detachment.
After the incubation, the medium was removed and cells were washed with PBS. Cell
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fixation and permeabilization was carried out with 70% cold methanol for 30 min at−20 ◦C,
and the chambers were washed with 1% PBS. Cells were rinsed three times with 1% BSA
and 0.02% sodium azide in PBS and blocked for 30 min at room temperature with the
same solution. The primary antibody to detect activated casapase-3 (rabbit polyclonal to
cleaved caspase-3 (Asp175), (Cell Signaling Technology, Danvers, MA, USA) was dissolved
in 0.5% BSA and 0.1% sodium azide in PBS and added to the chambers as 1:400 dilution.
Cells were incubated with primary antibodies overnight at 4 ◦C. The next day, chambers
were washed with 1% BSA and 0.02% sodium azide in PBS three times before addition
of the secondary antibody. Cells were incubated with goat anti-rabbit Alexa Fluor 594
(Invitrogen) diluted at 1:200 in PBS supplemented with 0.5% BSA and 0.1% sodium azide
for 45 min at room temperature. After three rinses with 1% BSA and 0.02% sodium azide
in PBS, cells were incubated with 4,6-diamidino-2-phenylindole (DAPI) (Sigma-Aldrich)
for 15 min at room temperature at a concentration of 1 µg/mL in PBS to stain the nuclei.
Lastly, cells were rinsed with PBS twice, kept in the same solution at 4 ◦C and viewed
with a confocal microscope LSM 800 (Zeiss, Birmingham, UK) using a Plan Apochromat
20× NA 0.8 objective (Zeiss).
4.8. Western Blot Analysis
Western Blot was used to detect activated caspase-3 in controls and in A2058 melanoma
cells and primary melanocytes treated with 20 µM PB; 106 cells/well of A2058 and
melanocytes were plated in 6-well microplate in 2 mL DMEM supplemented with 10% FBS
and incubated overnight at 37 ◦C. The following day, the medium was replaced by 2 mL
DMEM supplemented with 1% FBS and 0.9% DMSO in the absence (controls) and presence
of 20 µM PB and A2058 and primary melanocytes were incubated for 12 h. Cells were lysed
in RIPA buffer supplemented with protease inhibitors. The total protein concentrations
were measured by DC protein assay (Bio-Rad), and equal amounts of proteins (25 µg) were
resolved by SDS PAGE and transferred to a nitrocellulose membrane (Life Technology,
Alcobendas, Spain). Blots were incubated with PBS containing 5% Bovine Serum Albu-
min and 0.1% Tween-20 for 1 h to block non-specific binding. Proteins were probed with
cleaved caspase-3 (Cell Signaling Technology) rabbit monoclonal specific antibody (dilu-
tion 1:1000) to detect activated caspase-3, followed by an anti-rabbit secondary antibody
(Invitrogen) (dilution 1:1000) conjugated with HRP. After mild stripping, the membrane
was analyzed with mouse monoclonal GAPDH specific antibody (Abcam, Cambridge, UK)
(dilution 1:1000), followed by an anti-mouse secondary antibody (Cell Signaling Technol-
ogy) (dilution 1:1000) conjugated with HRP. The HRP signals were developed by using
by enhanced chemiluminescence using the SuperSignal® West Pico Chemiluminescent
Substrate (Thermo Scientific, Rockford, IL, USA).
4.9. Viability Assays
Two colorimetric assays were used to study the cytotoxic effects of the selected com-
pounds: the XTT Cell Proliferation Kit II (Roche) and Presto Blue™ Cell Viability Reagent
(Invitrogen). Exponentially growing cell lines seeded at 20,000 cells/well in 96-well flat
bottom plates (Sarstedt) were incubated overnight in 150 µL of the corresponding growth
medium. The following day, the medium was replaced by fresh medium (150 µL) con-
taining 1% FBS (except for melanocytes) and 0.9% DMSO in the presence or absence of
different concentrations of compounds. A2058 and MeWo cells were treated with increasing
compound concentrations for cell viability assays. In the case of primary melanocytes
and fibroblasts, one concentration was tested for each compound: 40 µM compound 2,
40 µM compound 4, and 20 µM compound 5. Cells were incubated for 4.5, 8, and 12 h
with subsequent addition of XTT (50 µL) or Presto Blue (17 µL) to each well followed
by an incubation for 4 or 2 h, respectively. Cell viability in plates treated with XTT was
determined by reading the absorbance at 490 nm in a Synergy HTX plate reader (BioTek).
Viability in plates treated with Presto Blue was determined in the same manner but results
were obtained by subtracting the absorbance at 570 nm to that obtained at 620 nm. In both
Cancers 2021, 13, 2936 18 of 24
cases, the absorbance of the medium was subtracted from cell-containing wells. Control
values (without compounds but with 0.9% DMSO) were taken as 100% viability.
4.10. Time-Lapse Imaging
A2058 and MeWo cell lines were treated with 40 µM PB, for time-lapse live cell imaging
to analyze the morphological changes they underwent prior to cell death. Moreover,
300,000 A2058 and MeWO melanoma cells were seeded in culture medium (2 mL DMEM
supplemented with 10% FBS) in a 35 mm glass bottom dish (µ-Dish 35 mm, Ibidi) and
allowed to attach overnight. Cells were incubated in 2 mL DMEM supplemented with
1% FBS, 0.9% DMSO and 40 µM PB. This culture was recorded by taking photos at a 20×
magnification (10 different frames per dish) every 10 min during 8 (A2058) or 24 h (MeWO)
with the BioStation IMQ live-cell time-lapse microscopy (Nikon Instruments B.V.) at 37 ◦C
and 5% CO2.
4.11. Homology Modeling
The first step to generate the homology models was to search for the best templates
using the SWISS-MODEL web server [95]. Two models (ADP and ATP state) were gen-
erated for Hsc70 and Hsp70, as these states adopt different structures. The ADP state
of Hsp70 was generated using PDB ID 2KHO.A as template [96], and its ATP state with
PDB ID 6ASY.A [97]. The ADP state of Hsc70 was modeled using PDB IDs 1YUW.A [98]
and PDBID 2KHO.A [96] as templates, and its ATP state using PDB IDs 5E84.A [99] and
1KAX.A [100]. The template used for Apg2 was PDB ID 3C7N.A [101]. Then, the templates
were aligned with the sequences of the query proteins considering the structure. Those
structure-based alignments were employed to generate models using MODELLER [102].
Different models were obtained for each protein, and all of them were analyzed by ER-
RAT [103], Verify-3D [104], and WHAT-IF [105] to assess their quality. Finally, the best
models were energy minimized using OMMProtocol [106], achieving good quality initial
homology models.
4.12. Protein–Ligand Docking
A first docking round was performed to search for the most probable binding sites
for the ligand using GaudiMM [58]. These results, considering the DSF results, were
used to select the most suitable binding regions for a more detailed docking study using
GOLD5.8 [59], and evaluated with the ChemScore scoring function [107]. Rotamers for
residues occupying the active site were applied using the Dunbrack library [108].
4.13. Molecular Dynamics Simulations
Molecular Dynamics (MD) simulations of the best docking result (Hsc70-ATP state)
were performed to ensure the stability of the ligand-protein complex and to potentially re-
fine the initial protein–ligand docking through the exploration of the conformational space.
The complex was prepared for the all-atoms MD simulations: the histidines predicted to
be in a region of higher pH than 6.0 by the H++ server [109] were protonated in the initial
models and the system was set up with XLeap [110]. Explicit solvent was used for initial
simulations, and Na+ ions were added to obtain charge neutrality. The model system was
embedded into a cubic box with a distance of 6 Å between the protein and the box edge,
containing around 60,000 water molecules.
AMBER ff99SBildn [111] and TIP3P [112] force fields were used for proteins and
water, respectively, and the parameters for the ions used to neutralize the system were
taken from ions94.lib library. Parameters for ATP, Mg2+ and K+ were not included in
AMBER18 by default, so they were taken from the literature [113,114]. In the case of the PB
ligand, parameters were developed according to standard approaches. Point charges were
calculated with antechamber [115] according to the RESP procedure [116] and GAFF force
field was adopted for the remaining atoms [117].
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MD simulations were performed with OpenMM [118]. A cutoff of 1 nm was used
for short-range electrostatics and Van der Waals interactions. Long-range electrostatic
interactions were calculated with the particle mesh Ewald (PME) method, using periodic
boundary conditions [119]. Bonds involving hydrogen atoms were constrained using the
SHAKE algorithm [120]. A time step of 1 fs was used to integrate the equation of motion
with a Langevin integrator [121]. Constant temperature and pressure were achieved
by coupling the systems to a Monte Carlo barostat at 1.01325 bar [122]. Model system
was energy minimized before starting the MD simulations, allowing movement of water
molecules, sidechains, and backbone atoms. Then, temperature was increased from 100 K
to 300 K and 100 ns MD simulations were carried out. Molecular graphics were made with
the UCSF Chimera package [61].
4.14. Statistical Analysis
All measurements were performed at least three times and levels of significance were
determined by a two-tailed Student’s t-test. A value of p < 0.05 was considered statistically
significant (* p < 0.05; ** p < 0.01).
5. Conclusions
The findings from this study show that pinaverium bromide inhibits the intracellular
activity of the Hsp70 system, which could be one of its targets, inducing specifically the
death of two melanoma cell lines without being cytotoxic for non-tumorigenic cells. They
support further clinical investigations in mouse melanoma models to explore the possibility
of adding this compound to the therapeutic arsenal for melanoma treatment.
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